Tigermed sees net profit nearly double in Q3 2025

Hangzhou Tigermed Consulting Co., Ltd. reported a net profit attributable to shareholders of CNY 637,097,023.97 for the third quarter of 2025, marking a 98.73% increase compared to the previous year. Year-to-date, this figure reached CNY 1,020,434,157.81, up 25.45%. Operating revenue for the quarter was CNY 1,775,423,981.12, a modest 3.86% increase, while year-to-date operating revenue saw a slight decline of 0.82% to CNY 5,025,868,260.75.

Net cash generated from operating activities for the year-to-date period significantly improved to CNY 739,557,629.57, representing a 27.78% increase. Basic and diluted earnings per share for the quarter both increased by 100% to CNY 0.74. Investment income for the year-to-date period soared to CNY 440,220,795.12, a 303.29% increase, primarily due to higher investment returns from associates and gains from other non-current financial assets.

The company's total assets grew by 0.39% to CNY 28,784,251,786.89 by the end of the reporting period. Notably, the sale of its 95.09% stake in Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. to Chia Tai Pharmaceutical Investment (Beijing) Group Co., Ltd. for approximately $34.11 million was approved in July 2025.